Should I Get a Pneumonia Vaccination in the UK?

If you are 65 or older, or you have a long-term health condition that puts you at higher risk, the answer is a clear yes. The UK’s national immunisation programme offers pneumococcal vaccination free on the NHS to everyone turning 65 and to younger adults and children with certain clinical risk factors. Pneumonia accounts for roughly 29,000 deaths a year in the UK, and the available vaccines offer meaningful, if not perfect, protection against the most common bacterial cause.

Why Pneumonia Is Still a Serious Problem in the UK

Pneumonia sometimes gets dismissed as a disease of the past, but the numbers tell a different story. Hospital admissions for pneumonia in England rose by about a third between the late 1990s and mid-2000s, with the sharpest increase among older adults, who also had the highest death rates.¹ The most common bacterial culprit is Streptococcus pneumoniae, a germ with over 90 distinct subtypes. Community-acquired pneumonia caused by this organism is often non-invasive, meaning it does not show up in bloodstream tests, so reported figures almost certainly undercount the real burden.² Among patients admitted to hospital with pneumonia, somewhere between 5 and 15 percent die within 30 days.² That is a striking fatality rate for something a vaccine can partly prevent.

Who Is Eligible on the NHS

The UK’s programme has two main groups. The first is everyone turning 65: you are offered the vaccine once, usually through your GP surgery. The second group covers people of any age (including children) who have conditions that raise their risk. The strongest risk factors for serious pneumococcal disease in England are chronic liver disease, immunosuppression, and chronic respiratory conditions like COPD or severe asthma.³ Diabetes, heart disease, kidney disease, a missing or non-functioning spleen, and cochlear implants also qualify. If you are unsure whether you are in a risk group, your GP practice will usually have a record of it and may invite you proactively.

Despite these broad eligibility criteria, uptake is uneven. England’s official coverage data for 2024–25 puts overall coverage at about 74 percent among people aged 65 and over, but only about 48 percent among younger adults in clinical risk groups.⁴ Coverage varies by condition too: people with cochlear implants have the highest rate, at about 70 percent, while those with chronic liver disease sit lowest at around 39 percent.⁴ A big part of that gap is simply awareness: younger adults in a risk group are almost half as likely to get vaccinated compared with those who are both over 65 and have an additional risk condition.⁵

Which Vaccines Are Used and How They Differ

For decades the standard adult pneumococcal vaccine in the UK has been PPV23, a polysaccharide vaccine that targets 23 of the most common bacterial subtypes. It works by presenting fragments of the pneumococcal outer coating to your immune system, which then produces antibodies. PPV23 is cheap, well-established, and broadly protective, but it has a well-known limitation: it does not trigger the kind of immune memory that gets stronger over time. The immune response it creates tends to fade within a few years.

Conjugate vaccines are a newer technology. They attach the same sugar fragments to a carrier protein, which teaches the immune system to respond more robustly and with longer-lasting memory. The UK already uses conjugate vaccines in babies (currently PCV13), and a 20-valent conjugate vaccine, PCV20, has recently been licensed for adults.⁶ In clinical trials, PCV20 produced immune responses at least as strong as PCV13 for the 13 shared subtypes, and strong responses to the seven additional subtypes as well.⁷ A head-to-head comparison of PCV13 and PPV23 in vaccine-naïve adults found that the conjugate vaccine produced stronger functional antibody responses for the majority of shared subtypes.⁸

Economic modelling in England has found that both PPV23 and PCV20 are cost-effective when offered to adults at 65 or 75.⁹ A separate analysis looking at a switch from PPV23 to PCV20 for all adults over 65 and at-risk younger adults concluded the change would actually be cost-saving from a wider societal perspective, factoring in fewer hospital admissions and less time off work for carers.¹⁰ UK policy is evolving, and PCV20 may replace or supplement PPV23 for adults in the coming years.

How Much Protection Does the Vaccine Actually Provide

No vaccine prevents every case, and that is especially true of pneumococcal vaccines because there are so many bacterial subtypes, and the vaccines only cover a fraction. Still, the evidence from UK real-world data is reasonably encouraging. A large cohort study using English GP records found that PPV23 reduced the risk of community-acquired pneumonia in vaccinated over-65s. The effect was moderate: the risk dropped by roughly 14 percent in the 65–74 age group and by about 35 percent in those over 80.¹¹ The fact that protection appeared greater in older people, who are most vulnerable, is a useful feature.

Against invasive pneumococcal disease, which is the most dangerous form where bacteria enter the blood or brain, PPV23 showed about 27 percent overall effectiveness in adults 65 and over in England and Wales, rising to about 41 percent in the first two years after vaccination and falling to about 23 percent after five years.¹² People without underlying health conditions got the most benefit, with protection around 45 percent.¹² Those numbers might sound modest compared with, say, a measles vaccine, but when you are talking about a disease that kills thousands of older adults each year, even moderate protection saves a lot of lives.

How Long Does Protection Last

This is one of the less satisfying parts of the story. PPV23 protection wanes, and there is real debate about what to do about it. The decline from about 41 percent effectiveness in the first two years down to 23 percent after five years is substantial.¹² A long-term follow-up study of frail, hospitalised older adults found that while antibody levels remained high six years after vaccination, the functional activity of those antibodies had waned considerably.¹³ That distinction matters because what protects you is not just how many antibodies you have but how well they work.

The obvious question, then, is whether a booster dose helps. An English population-based cohort study found no clear benefit from a second dose of PPV23 in older adults, though the researchers cautioned that the small number of revaccinated people in the data limited the strength of their conclusions.¹⁴ This is a known problem with polysaccharide vaccines: repeated doses can actually produce a weaker response than the first, a phenomenon sometimes called hyporesponsiveness. It is one of the reasons conjugate vaccines like PCV20 are attractive for adults, since they are designed to build genuine immune memory. Whether the UK programme will move toward offering a conjugate booster to adults who already had PPV23 remains an active policy question.

Safety and Side Effects

Pneumococcal vaccines have been in use for decades, and their safety record is strong. The typical side effects are the ones you would expect from any jab: a sore arm, mild fever, and tiredness for a day or two. Serious adverse reactions are exceedingly rare. Since the polysaccharide vaccine became commercially available in 1977, fewer than ten published case reports have described serious side effects in adults after a first dose.¹⁵

One specific concern people with autoimmune conditions sometimes raise is whether the vaccine could trigger a flare of their disease. A UK-wide study of adults with immune-mediated inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease, found no increase in joint pain, rheumatic disease flares, or IBD flares after pneumococcal vaccination.¹⁶ That is reassuring, because people on immunosuppressive treatment are precisely the group most vulnerable to pneumococcal disease and most likely to benefit from vaccination.

What Pneumococcal Vaccines Do Not Cover

A common misconception is that “the pneumonia jab” protects you against all pneumonia. It does not. Pneumonia can be caused by many different organisms, including viruses like influenza and respiratory syncytial virus (RSV), other bacteria, and fungi.¹⁷ Pneumococcal vaccines protect only against the specific subtypes of Streptococcus pneumoniae included in the vaccine formula. Even within pneumococcal disease, the vaccine cannot cover every subtype: there are over 90, and the broadest current vaccine, PPV23, covers 23 of them.

This means that getting vaccinated substantially lowers your risk of the most common and dangerous forms of bacterial pneumonia but leaves you vulnerable to less common subtypes and non-pneumococcal causes. Flu vaccination is an important complement, since influenza often sets the stage for a secondary bacterial pneumonia. If you are in a risk group for pneumococcal vaccination, you almost certainly qualify for a free annual flu jab too, and the two work well together.

How Childhood Vaccination Helps Adults

You might wonder what baby vaccines have to do with your risk as an adult. Quite a lot, as it turns out. Young children are the main carriers of pneumococcal bacteria, spreading them through coughs and close contact in nurseries and schools. When the UK introduced childhood pneumococcal conjugate vaccination, it did not just protect the children: it reduced the amount of bacteria circulating in the whole population. After the introduction of PCV7 in children, invasive pneumococcal disease caused by the vaccine subtypes dropped by 81 percent in people aged 65 and over.¹⁸ Early modelling had anticipated this: a UK analysis predicted that a childhood programme would prevent over 1,100 adult deaths from serious pneumococcal infection over ten years.¹⁹

There is a catch, though. As vaccine subtypes recede, non-vaccine subtypes move in to fill the gap. After childhood PCV7 was introduced in England and Wales, non-vaccine-subtype invasive disease rose by about 48 percent in people over 65.¹⁸ The net effect was still a 19 percent overall reduction in invasive disease in that age group, so the gains were not wiped out, but serotype replacement is a real and ongoing phenomenon.²⁰ This is exactly why vaccine manufacturers keep developing higher-valency vaccines covering more subtypes: PCV13, PCV15, PCV20, and soon potentially PCV21 are all attempts to stay ahead of the bacterial population shifting in response to vaccination pressure.

The Antibiotic Resistance Connection

An underappreciated benefit of pneumococcal vaccination is its effect on antibiotic resistance. When people get pneumonia, doctors prescribe antibiotics, and overuse of antibiotics is the main driver of resistant bacteria. By preventing infections in the first place, vaccines reduce the total volume of antibiotics prescribed. After childhood conjugate vaccines were introduced in the UK, antibiotic prescribing for ear infections in children, which are often caused by the same pneumococcal bacteria, dropped by about 73 percent over a decade.²¹ The introduction of PCV13 led to an additional 12 percent drop in antibiotic prescribing for ear infections on top of the reductions already seen.²¹ Surveillance data from the UK and Ireland show that vaccines play an important role in tackling antimicrobial resistance by reducing both infection rates and the unnecessary prescribing that fuels resistance.²² In an era when drug-resistant infections are a growing concern, this is a meaningful bonus.

Why Some People Hesitate

If you have been offered the vaccine and have not taken it up, you are not alone. Among younger adults in clinical risk groups in England, fewer than half are vaccinated.⁴ Research into vaccine hesitancy among older adults with chronic diseases found that the strongest predictors of refusing the vaccine were low confidence in the vaccine itself and a weak sense of collective responsibility, meaning people who did not feel that getting vaccinated protects others around them.²³

Some of the hesitancy is also structural. Many people in risk groups, particularly younger adults, are simply unaware they qualify. Unlike the flu jab, which most GP surgeries actively push each autumn, pneumococcal vaccination is a one-off event that can fall through the cracks. If you have a qualifying condition and have never been offered the jab, it is worth asking your GP practice or pharmacist directly. Community pharmacies have increasingly been recognised as a way to improve vaccine accessibility for adults who might not visit their GP frequently.²⁴

Getting Vaccinated Alongside Flu and COVID Jabs

A practical question many people have is whether they can get their pneumococcal, flu, and COVID vaccines at the same time. Co-administration is generally considered safe and is commonly offered in practice. A study of nursing home residents over 65 found that receiving pneumococcal and influenza vaccines alongside the COVID vaccine was associated with lower rates of hospitalisation and COVID-related death compared with the COVID vaccine alone.²⁵ That does not mean the pneumococcal vaccine protects against COVID per se. Rather, people whose immune systems are well-supported by a comprehensive vaccination programme seem to fare better overall when they do get sick.

If you are due your pneumococcal vaccination and an autumn flu or COVID jab is coming up, there is no reason not to get them in the same visit. You may get a sore arm on both sides, but there is no evidence that co-administration reduces how well any of the vaccines work or increases the risk of side effects beyond mild local reactions.

Care Homes and the Oldest Adults

People living in care homes deserve special mention. They are among the most vulnerable to pneumococcal disease, yet they face specific barriers to vaccination: mobility limitations, cognitive impairment that complicates consent, and the simple administrative challenge of making sure every resident’s vaccination record is up to date. A recent observational study in England explored the potential benefits of offering an additional pneumococcal vaccine to new residents entering older adult care homes, reflecting a growing recognition that this population may be particularly underserved by a one-off vaccination at age 65.⁶ If you have a family member in residential care, checking with the home about their pneumococcal vaccination status is a reasonable and often overlooked step.